Oncology On-The-Go Podcast: SGO 2023 Recap

Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.

In a Twitter Spaces edition of the Oncology On-The-Go podcast, Ritu Salani, MD, and Dana Chase, MD, spoke with CancerNetwork® about findings presented at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, and how they may impact clinical practice.

Salani, the Gynecologic Oncology Fellowship Director at University of California Los Angeles (UCLA) Health and the Gynecologic Oncology editorial board member for the journal ONCOLOGY®, and Chase, associate professor of UCLA Obstetrics and Gynecology in the Division of Gynecologic Oncology, reviewed data from trials including the phase 3 NRG GY018 trial (NCT03914612), the phase 3 RUBY trial (NCT03981796), and the phase 3 ENGOT-OV16/NOVA study (NCT01847274).

Don’t forget to subscribe to the “Oncology On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.